Read More

Compass cuts 30% of staff as late-stage psilocybin drug trials face new delays

Compass Pathways (NASDAQ: CMPS) plans to cut about 30% of its workforce and halt early-stage research programs as the firm focuses resources on completing late-stage trials of its lead COMP360 program. The London-based company announced the restructuring alongside third-quarter financial results that showed a widening net loss of $38.5 million …

Read More

Martech Prototypes: The Benefits of a ‘Sandbox Culture’

Imagine a child’s sandbox—a secure area where they can freely experiment and play without endangering themselves or the environment. Comparably, without the dangers of real software systems, digital sandboxes provide a safe setting for testing new software features, solving problems, doing cybersecurity evaluations, and giving practical user training. These sandbox …